. . . . "2010-09-01+02:00"^^ . "The blood samples of women with diagnosis of breast cancer will be immunocytochemicaly analyzed for circulating tumor cells. Frequency of CTC will be compared with different breast cancer stages and with basic prognostic factors (node involvement, tumor grade, expression of hormonal receptors and HER2/neu) at time of diagnosis, after primary treatment and every year. After three years of project the association between frequency of CTC, stage of the disease, type of treatment and clinical outcome of patients will be evaluated."@en . . . "Mo\u017Enosti detekce a v\u00FDznam mikrometast\u00E1z karcinomu prsu v perifern\u00ED krvi." . "NT11404" . . . "Hematogeneous micrometastases from breast cancer and its significance for clinical outcome and possibilities of next treatment."@en . . "U v\u0161ech pacientek podstupuj\u00EDc\u00EDch chirurgick\u00FD v\u00FDkon bude provedeno vy\u0161et\u0159en\u00ED na p\u0159\u00EDtomnost CTC bun\u011Bk. Bude porovn\u00E1na frekvence v\u00FDskytu CTC bun\u011Bk podle n\u00E1dorov\u00FDch stadi\u00ED a bude porovn\u00E1na s ostatn\u00EDmi %22klasick\u00FDmi%22 prognostick\u00FDmi a prediktivn\u00EDmi faktory (velikost n\u00E1doru, posti\u017Een\u00ED uzlin, grade, exprese hormon\u00E1ln\u00EDch receptor\u016F, stav angiogeneze prim\u00E1rn\u00EDho n\u00E1doru, exprese HER2/neu prim\u00E1rn\u00EDho n\u00E1doru). Obdobn\u00E9 vy\u0161et\u0159en\u00ED bude provedeno po skon\u010Den\u00ED prim\u00E1rn\u00ED l\u00E9\u010Dby a pot\u00E9 v ro\u010Dn\u00EDch intervalech. Na konci projektu bude vyhodnocen vztah mezi frekvenc\u00ED CTC, st\u00E1diem n\u00E1doru, typem l\u00E9\u010Dby a pr\u016Fb\u011Bhem nemoci." . "2014-12-31+01:00"^^ . . . . "http://www.isvav.cz/projectDetail.do?rowId=NT11404"^^ . " breast cancer" . . "1"^^ . "0"^^ . . "1"^^ . "0"^^ . "circulating tumor cell (CTC); breast cancer; micrometastases; disseminated tumor cell (DTC)"@en . "2015-01-22+01:00"^^ . " micrometastases" . . "circulating tumor cell (CTC)" . . "2013-03-26+01:00"^^ . "0"^^ . .